Pharmacoeconomic evaluation of osimertinib in the first-line treatment of locally advanced or metastatic NSCLC with an EGFR mutation

LIU Xinyi, CHEN Wen

PDF(2158 KB)
主办：上海医药工业研究院
　　　中国药学会
ISSN 1672-9188   CN 31-1939/R   SLYHAA
World Clinical Drug
PDF(2158 KB)
World Clinical Drug ›› 2021, Vol. 42 ›› Issue (02) : 135-142. DOI: 10.13683/j.wph.2021.02.010
Article

Pharmacoeconomic evaluation of osimertinib in the first-line treatment of locally advanced or metastatic NSCLC with an EGFR mutation

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2021, 42(02): 135-142 https://doi.org/10.13683/j.wph.2021.02.010

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(2158 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉